CoreAge Rx advertises sermorelin from $99 per month. Healthon’s reviewed pages display starting figures of $155 per month for injection and $135 for ODT, alongside out-of-stock text. Those listings identify advertised options, but they do not confirm what a particular patient can order today.

CoreAge Rx receives featured commercial placement on this site. We checked public information on September 20, 2026, without purchasing treatment or testing either preparation. This is a comparison of published offers and care questions, not a clinical ranking of the two providers.

The considered take

Confirm current availability and the selected plan before comparing price. A product card, stock label, and eligibility button answer different questions.

Starting prices do not settle the complete commitment

Healthon's pages contain plan and billing language alongside the starting figures. Ask which term produces the displayed rate, what is charged upfront, and what later renewals cost. For CoreAge Rx, obtain the same details for its advertised $99 starting price.

Do not compare only the two lowest numbers if one assumes a longer term, another is introductory, or the products use different routes. Include testing, consultation, supplies, and shipping where relevant. The cost guide provides a consistent list of the amounts and services to confirm before paying.

Availability needs confirmation for the actual product

The retrieved Healthon material included out-of-stock labels while still presenting an eligibility pathway. That combination does not establish current dispensing availability for a specific order. A webpage can contain text for several interface states, and a qualification form may be separate from pharmacy inventory.

Ask whether the proposed product is currently available in your state, whether payment creates a waitlist entry, and what happens if it cannot be supplied. Confirm those details with CoreAge Rx too. Neither provider's marketing page is a substitute for an order-specific answer about the preparation and expected fulfillment.

ODT convenience needs its own evidence discussion

Healthon publishes both injectable and orally disintegrating tablet information. CoreAge Rx's reviewed sermorelin material describes injection treatment. Ask the clinician which route is proposed and whether the finished product includes additional active ingredients.

The same ingredient name does not establish therapeutic equivalence across routes. Language about an online eligibility process also does not remove the need for a valid prescription for the dispensed medication. Read the tablets versus injections article and prescription guide before interpreting convenience language as a clinical recommendation.

Ask who handles a question after delivery

For both services, identify the prescriber, dispensing pharmacy, and contact route for an unexpected symptom or storage problem. Customer service can resolve account issues, while a clinician or pharmacist may need to answer the medical or product question.

The Healthon review and CoreAge Rx review provide the full public-information context. Compare written replies and a complete quote. We have not measured either service's response times, verified a patient-specific dispensing date, or established a difference in clinical effectiveness or medication quality.

Sources behind this article

Provider pages describe their own services. They are not independent proof of health outcomes. Pricing and availability can change.

  1. Healthon: Sermorelin injectionProvider primary source · Checked September 20, 2026. Advertised offering only; checkout, patient suitability, and dispensing were not tested.
  2. Healthon: Sermorelin ODTProvider primary source · Checked September 20, 2026. Advertised offering only; checkout, patient suitability, and dispensing were not tested.
  3. CoreAge Rx: Sermorelin product pageProvider primary source · Live product page; starting price is not a verified checkout total.
  4. HHS: Telehealth licensing across state linesUS government guidance · Licensure options depend on the patient location and state rules.
  5. Mayo Clinic: Sermorelin injection informationClinical or regulatory reference · Checked September 20, 2026. Findings apply to the specified molecule, route, and population.
  6. FDA: Risks of compounded drugsUS regulator · Explains lack of FDA approval and the risks of poor-quality compounded preparations.
  7. FDA: Safe drug use after a natural disasterUS regulator · General temperature-exposure guidance. Does not establish a sermorelin stability window or injectable reconstitution method.
  8. FDA: Managing the benefits and risks of medicinesUS regulator · General questions for evaluating benefit, follow-up and new medicines.